In this interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Sundar Jagannath, MD, professor of medicine at the Icahn School of Medicine at Mount Sinai in New York discusses what cure means in multiple myeloma and why there is an urgent need for a formal definition for it in the field.
The development of CAR-T cellular therapies and bispecific antibodies has produced deep, sustained MRD-negative remissions that can last five years or longer without patients needing ongoing treatment. Dr. Jagannath explained how calling these outcomes a “cure” gives patients hope, changes physician mindset and approach, drives clinical trial participation, encourages collaboration within the pharmaceutical industry, and helps regulators approve powerful new drugs earlier in the treatment journey.
Dr. Jagannath also lays out a precise, practical definition of “cure” in multiple myeloma that works for both newly diagnosed and relapsed patients.
